Open AccessPost‐COVID‐19 co‐morbidity of emerged Lophomonas infection and invasive pulmonary aspergillosis: First case report
Author(s) -
Sharifpour Ali,
Zakariaei Zakaria,
Fakhar Mahdi,
Banimostafavi Elham Sadat,
Nakhaei Maryam,
Soleymani Mostafa
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4822
Subject(s) - medicine , covid-19 , pulmonary aspergillosis , aspergillosis , pulmonary infection , intensive care medicine , immunology , pathology , infectious disease (medical specialty) , disease , outbreak
Due to long corticosteroid therapy in patients with COVID‐19, in case of cough, dyspnea, and weight loss, emerging pulmonary aspergillosis and lophomoniasis should be ruled out.